The Clinical Evaluation of the Dose of Erythropoietins Trial
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life
in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are
the most used treatment option.
The purpose of this study is
1. the evaluation of biochemical markers to determine the efficacy of individual prediction
of ESAs therapy
2. to determine the benefits and harms of different ESA doses therapeutic strategy for the
management of anaemia of end stage kidney disease (ESKD).